

Cytosorbents Corp  
Form 8-K  
April 05, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): April 1, 2016

**CYTOSORBENTS CORPORATION**

(Exact name of registrant as specified in its charter)

<b>Delaware</b> (State or other jurisdiction of incorporation)	<b>000-36792</b> (Commission File Number)	<b>98-0373793</b> (I.R.S. Employer Identification No.)
---	--	---

**7 Deer Park Drive, Suite K,**

<b>Monmouth Junction, New Jersey</b> (Address of principal executive offices)	<b>08852</b> (Zip Code)
--	----------------------------

Registrant's telephone number, including area code: (732) 329-8885

**Not Applicable**

Edgar Filing: Cytosorbents Corp - Form 8-K

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On April 1, 2016, the Board of Directors of CytoSorbents Corporation (the “Company”) approved the Company’s entry into the Fourteenth Amendment to Lease Agreement (the “Lease Amendment”) with Princeton Corporate Plaza, LLC, which extends the term of the Company’s 12,400 square foot lease for its corporate headquarters and manufacturing facility through May 31, 2017 and, effective June 1, 2016, the Company’s rent obligation shall be \$23,950 per month. In addition, the Lease Amendment provides the Company with an option to extend the term of the Lease Amendment for an additional year period through May 31, 2018 upon certain conditions.

The foregoing is a summary description of the terms of the Lease Amendment and does not purport to be complete, and it is qualified in its entirety by reference to the full text of the Lease Amendment, which the Company intends to file as an exhibit to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2016.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 5, 2016 CYTOSORBENTS  
CORPORATION

By: /s/ Dr. Phillip P. Chan  
Name: Dr. Phillip P. Chan  
President and  
Title: Chief Executive Officer